NXTC NextCure Inc
Price (delayed)
$0.4
Market cap
$11.2M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.99
Enterprise value
-$11.37M
NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases. Through its proprietary FIND-IO™ platform, NextCure studies various immune
Highlights
NXTC's debt is down by 13% year-on-year and by 4.4% since the previous quarter
The EPS has grown by 12% YoY and by 4.8% from the previous quarter
The quick ratio has plunged by 54% YoY and by 17% from the previous quarter
NextCure's equity has decreased by 43% YoY and by 13% QoQ
Key stats
What are the main financial stats of NXTC
Market
Valuations
Earnings
Shares outstanding
28.01M
Market cap
$11.2M
Enterprise value
-$11.37M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.17
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$59.75M
Net income
-$55.65M
EBIT
-$55.65M
EBITDA
-$52.23M
Free cash flow
-$41.28M
Per share
Balance sheet
Liquidity
EPS
-$1.99
EPS diluted
-$1.99
Free cash flow per share
-$1.48
Book value per share
$2.34
Revenue per share
$0
TBVPS
$2.89
Total assets
$80.86M
Total liabilities
$15.39M
Debt
$5.15M
Equity
$65.47M
Working capital
$62.23M
Debt to equity
0.08
Current ratio
7.5
Quick ratio
7.17
Net debt/EBITDA
0.43
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-57.2%
Return on equity
-68.4%
Return on invested capital
-80.2%
Return on capital employed
-78.1%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
NXTC stock price
How has the NextCure stock price performed over time
Intraday
-8.47%
1 week
-24.74%
1 month
-48.65%
1 year
-83.94%
YTD
-48.12%
QTD
-16.72%
Financial performance
How have NextCure's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$59.75M
Net income
-$55.65M
Gross margin
N/A
Net margin
N/A
NextCure's operating income has increased by 12% YoY and by 5% from the previous quarter
NXTC's net income is up by 11% year-on-year and by 4.9% since the previous quarter
Growth
What is NextCure's growth rate over time
Valuation
What is NextCure stock price valuation
P/E
N/A
P/B
0.17
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 12% YoY and by 4.8% from the previous quarter
The P/B is 68% lower than the 5-year quarterly average of 0.6 and 62% lower than the last 4 quarters average of 0.5
NextCure's equity has decreased by 43% YoY and by 13% QoQ
Efficiency
How efficient is NextCure business performance
NextCure's return on invested capital has shrunk by 60% YoY and by 17% QoQ
NXTC's return on equity is down by 46% year-on-year and by 9% since the previous quarter
NXTC's ROA is down by 34% YoY and by 7% QoQ
Dividends
What is NXTC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for NXTC.
Financial health
How did NextCure financials performed over time
NXTC's current ratio has dropped by 54% year-on-year and by 17% since the previous quarter
The quick ratio has plunged by 54% YoY and by 17% from the previous quarter
NXTC's debt is 92% smaller than its equity
The debt to equity has surged by 60% year-on-year and by 14% since the previous quarter
NextCure's equity has decreased by 43% YoY and by 13% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.